238. Vitamin D-resistant rickets Clinical trials / Disease details
Clinical trials : 28 / Drugs : 20 - (DrugBank : 9) / Drug target genes : 3 - Drug target pathways : 16
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03348644 (ClinicalTrials.gov) | August 1, 2015 | 9/10/2017 | Milk Products in the Treatment of Hypophosphatemic Rickets | Milk Products in the Treatment of Hypophosphatemic Rickets: A Randomised Crossover Trial | Hypophosphatemic Rickets | Dietary Supplement: Phosphate tablets.;Dietary Supplement: High cheese intake.;Dietary Supplement: High milk intake. | University of Aarhus | University of East Anglia;Kolding Sygehus;Aarhus University Hospital | Completed | 14 Years | N/A | Female | 7 | N/A | Denmark |
| 2 | JPRN-JapicCTI-101332 | 01/9/2010 | 02/11/2010 | Therapeutic use of Z-521 | Therapeutic use of oral sodium phosphate (Z-521) in primary hypophosphatemic rickets (familial rickets, X-linked hypophosphatemia, vitamin D-resistant rickets) | primary hypophosphatemic rickets | Intervention name : Z-521 Dosage And administration of the intervention : 300-3000mg inorganic phosphorus is orally administered in 3 or 4 times per day | Zeria Pharmaceutical Co., Ltd. | NULL | 1 | 14 | BOTH | 10 | Phase 3 | NULL | |
| 3 | NCT01237288 (ClinicalTrials.gov) | September 2010 | 7/11/2010 | Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets | Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets | Primary Hypophosphatemic Rickets | Drug: Z-521 | Zeria Pharmaceutical | NULL | Completed | 1 Year | 14 Years | Both | 16 | Phase 3 | Japan |
| 4 | NCT01057186 (ClinicalTrials.gov) | December 2009 | 26/1/2010 | Hypophosphatemic Rickets in Norway | Hypophosphatemic Rickets in Norway | Hypophosphatemia, Familial;Rickets;Hyperphosphatemia | Dietary Supplement: Alfacalcidol; phosphate.;Drug: Sevelamer | Haukeland University Hospital | NULL | Active, not recruiting | N/A | N/A | Both | 80 | N/A | Norway |
| 5 | ChiCTR-OOC-16010095 | 2006-01-01 | 2016-12-07 | Oral Phosphate Supplements Play an Important Role in Improving the Bone Mineral Density of Hypophosphatemic Osteomalacia Patients | Effect of Phosphate on hypophosphatemia | Hypophosphatemic Osteomalacia | A1:received phosphate solution doses at a frequency dependent upon measured serum phosphorus levels;A2:received phosphate solution doses only every three to four days;A3:received no phosphate solution;A:Hypophosphatemic Osteomalacia;B:Control; | The Second Xiangya Hospital, Central South University | NULL | Completed | Both | A1:3;A2:5;A3:3;A:21;B:105; | China | |||
| 6 | NCT00195936 (ClinicalTrials.gov) | June 2005 | 13/9/2005 | Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets | Effect of Calcimimetic (Cinacalcet) on Phosphate-Induced Hyperparathyroidism in Children With Hypophosphatemic Rickets | Hypophosphatemic Rickets, X-Linked Dominant | Drug: Cinacalcet | Children's Mercy Hospital Kansas City | NULL | Completed | 5 Years | N/A | All | 8 | Phase 1 | United States |